NCT07200596

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Subcutaneous Injection of SHR-3045 in Healthy Subjects-A Randomized, Double-Blind, Dose-Escalating, Placebo-Controlled Phase I Study

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.

Conditions

• Rheumatoid Arthritis (RA)

Interventions

Type	Name	Description
DRUG	SHR-3045 Injection	SHR-3045 injection.
DRUG	SHR-3045 Placebo Injection	SHR-3045 placebo injection.

Timeline

• Start date: 2025-10-08
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2025-10-01
• Last updated: 2025-11-17

Locations

1 site across 1 country: China